CIK 0001828185
BRNS Barinthus Biotherapeutics plc.
Insider trading from SEC Form 4. Last filing 31 d ago.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
11
with a Form 4 at this company
Signals
Open-market buys and sells at Barinthus Biotherapeutics plc., scored.
No scored open-market trades yet. Grants, exercises and other rows are below.
Transactions
The last 60 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 9, 2026 | Oxford Science Enterprises plc other | UTender of shares Ordinary Shares | -8,797,770 | $0.11 | $977k | 0 | 31 d ago |
| Sep 9, 2026 | Karen A Dawes director | DDisposition to issuer Ordinary Shares | -1,700 | - | - | 0 | 33 d ago |
| Sep 9, 2026 | Robin Wright director | DDisposition to issuer Ordinary Shares | -48,256 | - | - | 0 | 33 d ago |
| Sep 9, 2026 | William Enright Chief Executive Officer | DDisposition to issuer Ordinary Sharesindirect: By Trust | -728,454 | - | - | 0 | 33 d ago |
| Sep 9, 2026 | Joseph Scheeren director | DDisposition to issuer Ordinary Shares | -23,000 | - | - | 0 | 33 d ago |
| Sep 9, 2026 | Anne M. Phillips director | DDisposition to issuer Ordinary Shares | -3,000 | - | - | 0 | 33 d ago |
| Sep 9, 2026 | Pierre A. Morgon director | DDisposition to issuer Ordinary Shares | -10,506 | - | - | 0 | 33 d ago |
| Sep 9, 2026 | Alex Hammacher director | DDisposition to issuer Ordinary Shares | -3,000 | - | - | 0 | 33 d ago |
| Sep 9, 2026 | Leon Hooftman Chief Medical Officer | AGrant or award Ordinary Shares | +361,530 | - | - | 361,530 | 33 d ago |
| Sep 9, 2026 | Karen A Dawes director | DDisposition to issuer Share Option (Right to Buy)derivative | -34,328 | $0.00 | $0 | 0 | 33 d ago |
| Sep 9, 2026 | Robin Wright director | DDisposition to issuer Share Option (Right to Buy)derivative | -20,394 | $0.00 | $0 | 0 | 33 d ago |
| Sep 9, 2026 | Joseph Scheeren director | DDisposition to issuer Share Option (Right to Buy)derivative | -34,328 | $0.00 | $0 | 0 | 33 d ago |
| Sep 9, 2026 | Anne M. Phillips director | DDisposition to issuer Share Option (Right to Buy)derivative | -34,328 | $0.00 | $0 | 0 | 33 d ago |
| Sep 9, 2026 | Pierre A. Morgon director | DDisposition to issuer Share Option (Right to Buy)derivative | -20,394 | $0.00 | $0 | 0 | 33 d ago |
| Sep 9, 2026 | Leon Hooftman Chief Medical Officer | DDisposition to issuer Ordinary Shares | -361,530 | - | - | 0 | 33 d ago |
| Sep 9, 2026 | Alex Hammacher director | DDisposition to issuer Share Option (Right to Buy)derivative | -34,328 | $0.00 | $0 | 0 | 33 d ago |
| Sep 9, 2026 | William Enright Chief Executive Officer | DDisposition to issuer Ordinary Sharesindirect: By Trust | -514,923 | - | - | 0 | 33 d ago |
| Sep 9, 2026 | Joseph Scheeren director | DDisposition to issuer Share Option (Right to Buy)derivative | -18,604 | $0.00 | $0 | 0 | 33 d ago |
| Sep 9, 2026 | Karen A Dawes director | DDisposition to issuer Share Option (Right to Buy)derivative | -18,604 | $0.00 | $0 | 0 | 33 d ago |
| Sep 9, 2026 | Alex Hammacher director | DDisposition to issuer Share Option (Right to Buy)derivative | -18,604 | $0.00 | $0 | 0 | 33 d ago |
| Sep 9, 2026 | Leon Hooftman Chief Medical Officer | DDisposition to issuer Share Option (Right to Buy)derivative | -195,166 | $0.00 | $0 | 0 | 33 d ago |
| Sep 9, 2026 | Pierre A. Morgon director | DDisposition to issuer Share Option (Right to Buy)derivative | -34,328 | $0.00 | $0 | 0 | 33 d ago |
| Sep 9, 2026 | Anne M. Phillips director | DDisposition to issuer Share Option (Right to Buy)derivative | -18,604 | $0.00 | $0 | 0 | 33 d ago |
| Sep 9, 2026 | William Enright Chief Executive Officer | DDisposition to issuer Share Option (Right to Buy)derivative | -176,130 | $0.00 | $0 | 0 | 33 d ago |
| Sep 9, 2026 | Robin Wright director | DDisposition to issuer Share Option (Right to Buy)derivative | -34,328 | $0.00 | $0 | 0 | 33 d ago |
| Sep 9, 2026 | Alex Hammacher director | DDisposition to issuer Share Option (Right to Buy)derivative | -19,197 | $0.00 | $0 | 0 | 33 d ago |
| Sep 9, 2026 | Joseph Scheeren director | DDisposition to issuer Share Option (Right to Buy)derivative | -19,197 | $0.00 | $0 | 0 | 33 d ago |
| Sep 9, 2026 | Karen A Dawes director | DDisposition to issuer Share Option (Right to Buy)derivative | -19,197 | $0.00 | $0 | 0 | 33 d ago |
| Sep 9, 2026 | Anne M. Phillips director | DDisposition to issuer Share Option (Right to Buy)derivative | -19,197 | $0.00 | $0 | 0 | 33 d ago |
| Sep 9, 2026 | William Enright Chief Executive Officer | DDisposition to issuer Share Option (Right to Buy)derivative | -359,605 | $0.00 | $0 | 0 | 33 d ago |
| Sep 9, 2026 | Robin Wright director | DDisposition to issuer Share Option (Right to Buy)derivative | -18,604 | $0.00 | $0 | 0 | 33 d ago |
| Sep 9, 2026 | Pierre A. Morgon director | DDisposition to issuer Share Option (Right to Buy)derivative | -18,604 | $0.00 | $0 | 0 | 33 d ago |
| Sep 9, 2026 | Leon Hooftman Chief Medical Officer | DDisposition to issuer Share Option (Right to Buy)derivative | -140,000 | $0.00 | $0 | 0 | 33 d ago |
| Sep 9, 2026 | Pierre A. Morgon director | DDisposition to issuer Share Option (Right to Buy)derivative | -19,197 | $0.00 | $0 | 0 | 33 d ago |
| Sep 9, 2026 | William Enright Chief Executive Officer | DDisposition to issuer Share Option (Right to Buy)derivative | -440,000 | $0.00 | $0 | 0 | 33 d ago |
| Sep 9, 2026 | Anne M. Phillips director | DDisposition to issuer Share Option (Right to Buy)derivative | -19,516 | $0.00 | $0 | 0 | 33 d ago |
| Sep 9, 2026 | Robin Wright director | DDisposition to issuer Share Option (Right to Buy)derivative | -19,197 | $0.00 | $0 | 0 | 33 d ago |
| Sep 9, 2026 | Alex Hammacher director | DDisposition to issuer Share Option (Right to Buy)derivative | -19,516 | $0.00 | $0 | 0 | 33 d ago |
| Sep 9, 2026 | Joseph Scheeren director | DDisposition to issuer Share Option (Right to Buy)derivative | -19,516 | $0.00 | $0 | 0 | 33 d ago |
| Sep 9, 2026 | Karen A Dawes director | DDisposition to issuer Share Option (Right to Buy)derivative | -19,516 | $0.00 | $0 | 0 | 33 d ago |
| Sep 9, 2026 | Robin Wright director | DDisposition to issuer Share Option (Right to Buy)derivative | -19,516 | $0.00 | $0 | 0 | 33 d ago |
| Sep 9, 2026 | Karen A Dawes director | DDisposition to issuer Share Option (Right to Buy)derivative | -20,174 | $0.00 | $0 | 0 | 33 d ago |
| Sep 9, 2026 | Anne M. Phillips director | DDisposition to issuer Share Option (Right to Buy)derivative | -20,174 | $0.00 | $0 | 0 | 33 d ago |
| Sep 9, 2026 | Pierre A. Morgon director | DDisposition to issuer Share Option (Right to Buy)derivative | -19,516 | $0.00 | $0 | 0 | 33 d ago |
| Sep 9, 2026 | William Enright Chief Executive Officer | DDisposition to issuer Share Option (Right to Buy)derivative | -443,981 | $0.00 | $0 | 0 | 33 d ago |
| Sep 9, 2026 | Alex Hammacher director | DDisposition to issuer Share Option (Right to Buy)derivative | -20,174 | $0.00 | $0 | 0 | 33 d ago |
| Sep 9, 2026 | Joseph Scheeren director | DDisposition to issuer Share Option (Right to Buy)derivative | -20,174 | $0.00 | $0 | 0 | 33 d ago |
| Sep 9, 2026 | Pierre A. Morgon director | DDisposition to issuer Share Option (Right to Buy)derivative | -20,174 | $0.00 | $0 | 0 | 33 d ago |
| Sep 9, 2026 | William Enright Chief Executive Officer | DDisposition to issuer Share Option (Right to Buy)derivative | -600,000 | $0.00 | $0 | 0 | 33 d ago |
| Sep 9, 2026 | Robin Wright director | DDisposition to issuer Share Option (Right to Buy)derivative | -20,174 | $0.00 | $0 | 0 | 33 d ago |
| Jun 10, 2025 | Joseph Scheeren director | AGrant or award Share Option (Right to Buy)derivative | +20,174 | $0.00 | $0 | 20,174 | Jun 11, 2025 |
| Jun 10, 2025 | Alex Hammacher director | AGrant or award Share Option (Right to Buy)derivative | +20,174 | $0.00 | $0 | 20,174 | Jun 11, 2025 |
| Jun 10, 2025 | Robin Wright director | AGrant or award Share Option (Right to Buy)derivative | +20,174 | $0.00 | $0 | 20,174 | Jun 11, 2025 |
| Jun 10, 2025 | Pierre A. Morgon director | AGrant or award Share Option (Right to Buy)derivative | +20,174 | $0.00 | $0 | 20,174 | Jun 11, 2025 |
| Jun 10, 2025 | Anne M. Phillips director | AGrant or award Share Option (Right to Buy)derivative | +20,174 | $0.00 | $0 | 20,174 | Jun 11, 2025 |
| Jun 10, 2025 | Karen A Dawes director | AGrant or award Share Option (Right to Buy)derivative | +20,174 | $0.00 | $0 | 20,174 | Jun 11, 2025 |
| Feb 3, 2025 | Leon Hooftman Chief Medical Officer | AGrant or award Share Option (Right to Buy)derivative | +140,000 | $0.00 | $0 | 140,000 | Feb 5, 2025 |
| Feb 3, 2025 | Graham Griffiths Chief Business Officer | AGrant or award Share Option (Right to Buy)derivative | +200,000 | $0.00 | $0 | 200,000 | Feb 5, 2025 |
| Feb 3, 2025 | William Enright Chief Executive Officer | AGrant or award Share Option (Right to Buy)derivative | +600,000 | $0.00 | $0 | 600,000 | Feb 5, 2025 |
| Feb 3, 2025 | Gemma Brown Chief Financial Officer | AGrant or award Share Option (Right to Buy)derivative | +160,000 | $0.00 | $0 | 160,000 | Feb 5, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Gemma BrownChief Financial Officer
- Karen A Dawesdirector
- William EnrightChief Executive Officer
- Graham GriffithsChief Business Officer
- Alex Hammacherdirector
- Leon HooftmanChief Medical Officer
- Pierre A. Morgondirector
- Oxford Science Enterprises plcother
- Anne M. Phillipsdirector
- Joseph Scheerendirector
- Robin Wrightdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.